These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 12364631)

  • 1. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients.
    Bartolucci P; Ramanoelina J; Cohen P; Mahr A; Godmer P; Le Hello C; Guillevin L
    Rheumatology (Oxford); 2002 Oct; 41(10):1126-32. PubMed ID: 12364631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis.
    Lamprecht P; Voswinkel J; Lilienthal T; Nolle B; Heller M; Gross WL; Gause A
    Rheumatology (Oxford); 2002 Nov; 41(11):1303-7. PubMed ID: 12422004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab efficacy and safety against refractory systemic necrotising vasculitides: long-term follow-up of 15 patients.
    Josselin L; Mahr A; Cohen P; Pagnoux C; Guaydier-Souquières G; Hayem G; Job-Deslandre C; Liferman F; Pourrat J; Guillevin L
    Ann Rheum Dis; 2008 Sep; 67(9):1343-6. PubMed ID: 18445626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis.
    Booth A; Harper L; Hammad T; Bacon P; Griffith M; Levy J; Savage C; Pusey C; Jayne D
    J Am Soc Nephrol; 2004 Mar; 15(3):717-21. PubMed ID: 14978174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation.
    Booth AD; Jayne DR; Kharbanda RK; McEniery CM; Mackenzie IS; Brown J; Wilkinson IB
    Circulation; 2004 Apr; 109(14):1718-23. PubMed ID: 15037536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial.
    Keogh KA; Ytterberg SR; Fervenza FC; Carlson KA; Schroeder DR; Specks U
    Am J Respir Crit Care Med; 2006 Jan; 173(2):180-7. PubMed ID: 16224107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of TNFalpha blockade in relapsing vasculitis.
    Booth AD; Jefferson HJ; Ayliffe W; Andrews PA; Jayne DR
    Ann Rheum Dis; 2002 Jun; 61(6):559. PubMed ID: 12006335
    [No Abstract]   [Full Text] [Related]  

  • 8. Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis.
    Puéchal X; Miceli-Richard C; Mejjad O; Lafforgue P; Marcelli C; Solau-Gervais E; Steinfeld S; Villoutreix C; Trèves R; Mariette X; Guillevin L;
    Ann Rheum Dis; 2008 Jun; 67(6):880-4. PubMed ID: 18037625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of ANCA-associated vascularitides].
    Guillevin L; Pagnoux C
    Presse Med; 2007 May; 36(5 Pt 2):922-7. PubMed ID: 17408912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis.
    Cohen G; Courvoisier N; Cohen JD; Zaltni S; Sany J; Combe B
    Clin Exp Rheumatol; 2005; 23(6):795-800. PubMed ID: 16396697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy.
    Kavanaugh A; St Clair EW; McCune WJ; Braakman T; Lipsky P
    J Rheumatol; 2000 Apr; 27(4):841-50. PubMed ID: 10782805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study.
    Gerloni V; Pontikaki I; Gattinara M; Desiati F; Lupi E; Lurati A; Salmaso A; Fantini F
    Arthritis Rheum; 2005 Feb; 52(2):548-53. PubMed ID: 15693004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.
    Aletaha D; Bingham CO; Tanaka Y; Agarwal P; Kurrasch R; Tak PP; Popik S
    Lancet; 2017 Mar; 389(10075):1206-1217. PubMed ID: 28215362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Are anti-TNFAb indicated in systemic necrotizing vasculitides?].
    Guillevin L
    Rev Med Interne; 2005 Oct; 26(10):769-70. PubMed ID: 16039017
    [No Abstract]   [Full Text] [Related]  

  • 15. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey.
    De Bandt M; Sibilia J; Le Loët X; Prouzeau S; Fautrel B; Marcelli C; Boucquillard E; Siame JL; Mariette X;
    Arthritis Res Ther; 2005; 7(3):R545-51. PubMed ID: 15899041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Infliximab in aggressive and refractory rheumatoid arthritis. A pilot study].
    Caramaschi P; Canestrini S; Biasi D; Carletto A; Scambi C; Scarperi A; Bambara LM
    Recenti Prog Med; 2002 Jan; 93(1):19-24. PubMed ID: 11850995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
    Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
    JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-tumor necrosis factor therapy in patients with difficult-to-treat lupus nephritis: a prospective series of nine patients.
    Matsumura R; Umemiya K; Sugiyama T; Sueishi M; Umibe T; Ichikawa K; Yoshimura M;
    Clin Exp Rheumatol; 2009; 27(3):416-21. PubMed ID: 19604433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open-label study.
    Kiely PD; Johnson DM
    Rheumatology (Oxford); 2002 Jun; 41(6):631-7. PubMed ID: 12048288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deoxyspergualin in relapsing and refractory Wegener's granulomatosis.
    Flossmann O; Baslund B; Bruchfeld A; Tervaert JW; Hall C; Heinzel P; Hellmich B; Luqmani RA; Nemoto K; Tesar V; Jayne DR
    Ann Rheum Dis; 2009 Jul; 68(7):1125-30. PubMed ID: 18713783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.